Design Therapeutics stockholders elect three directors, ratify EY as auditor at 2022 annual meeting

Design Therapeutics, Inc.

Shareholders elected Heather Berger, Rodney Lappe, and John Schmid as Class I directors to serve until 2025.
Votes for Berger: 49,858,607; for Lappe: 49,543,074; for Schmid: 49,344,059; with ~1.94M broker non-votes each.
Ratification of Ernst & Young as independent auditor for FY2022 passed with 53,181,814 votes for, 542 against, 36 abstentions.
Meeting held June 15, 2022; 55,781,681 shares outstanding and entitled to vote as of record date April 18, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.